InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV

InflaRx N.V.

IFRX

0.00

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases
Capital Markets Day highlighting the promise and potential of izicopan in AAV and broader renal disorders now planned for summer 2026
The Company estimates it will have sufficient funds for currently planned clinical development activities and ongoing operations through 2029
InflaRx will continue to engage in dialog with potential collaborators to advance its development goals with izicopan across all geographies

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.